J&J's first-in-class Invokana gets FDA OK for type 2 diabetes

04/1/2013 | HealthDay News · Reuters · Wall Street Journal, The

The FDA approved Johnson & Johnson's Invokana, or canagliflozin, as an adjunct therapy to diet and exercise in adults with type 2 diabetes. The drug, from J&J unit Janssen Pharmaceuticals, is the first sodium-glucose co-transporter 2 inhibitor approved for diabetes. The approval was based on data from nine late-stage studies that showed improvements in hemoglobin A1c levels and fasting blood sugar levels.

View Full Article in:

HealthDay News · Reuters · Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD